Expert Interview
Discussing the commercial experience of ONIVYDE (irinotecan liposome injection) in pancreatic cancer
Ticker(s): IPSEF, MACK, IPN.XPARInstitution: Moffitt
- GI Medical Oncology Assistant Member, department of GI Oncology - Moffitt
- Completed Melanoma Immunology Fellowship at MD Anderson and recently completed Medical Oncology Fellowship at Moffitt
- specialize in the treatment of gastrointestinal cancers, with a focus on immunotherapy.
Roughly how many patients with pancreatic cancer do you manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely exciting) where would you rate your level of excitement for ONIVYDE?
Added By: c_adminHave you been following the NAPOLI-3 trial for first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma? What do you think about the likelihood of Onivyde being approved as a first-line treatment?
Added By: user9794eb2aWhen the NAPOLI-3 trial ph III data comes out (expected before end of this year), what does it need to show in terms of the endpoints to make a strong case for first-line treatment in terms of efficacy and / or safety profile?
Added By: user9794eb2aAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
